106 related articles for article (PubMed ID: 1591058)
1. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.
Martin M; Diaz-Rubio E; Casado A; Dominguez S; Sastre J
Eur J Cancer; 1992; 28(2-3):430-2. PubMed ID: 1591058
[TBL] [Abstract][Full Text] [Related]
2. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.
Diaz-Rubio E; Martin M; Rosell R; Valerdi JJ; Gonzalez-Larriba JL; Barriga JJ
Acta Oncol; 1991; 30(3):339-42. PubMed ID: 2036244
[TBL] [Abstract][Full Text] [Related]
3. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
5. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of the simultaneous blockade of the dopamine D-2, histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: results of a controlled trial.
Martin-Jimenez M; Diaz-Rubio E
Cancer Chemother Pharmacol; 1986; 18(2):168-71. PubMed ID: 2947734
[TBL] [Abstract][Full Text] [Related]
7. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
9. [Antiemetic treatments associated with antineoplastic chemotherapy].
Tres Sánchez A; Sáez Martínez MJ; Mayordomo Cámara JJ; Guillén Lloveria G; Sáenz Cusi A
An Med Interna; 1990 May; 7(5):229-32. PubMed ID: 2102716
[TBL] [Abstract][Full Text] [Related]
10. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of a five-drug antiemetic combination during chemotherapy regimens containing cisplatin or cyclophosphamide-doxorubicin.
Aydiner A; Onat H; Oztürk N; Aykan F; Inanc S; Topuz E; Dincol K
J Pain Symptom Manage; 1993 Apr; 8(3):126-31. PubMed ID: 8326162
[TBL] [Abstract][Full Text] [Related]
12. Results of two controlled studies on antiemetic combination against vomiting induced by 5-fluorouracil.
Martin-Jimenez M; Diaz-Rubio E; Sangro B
Tumori; 1987 Oct; 73(5):499-504. PubMed ID: 3318052
[TBL] [Abstract][Full Text] [Related]
13. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
[TBL] [Abstract][Full Text] [Related]
14. [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].
Park Y; Hatano Y; Sasamoto S; Kato N; Okuyama N; Yamazaki S
Gan To Kagaku Ryoho; 1997 Mar; 24(5):573-7. PubMed ID: 9087290
[TBL] [Abstract][Full Text] [Related]
15. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
16. [An antiemetic effect of methylprednisolone plus droperidol against nausea and vomiting caused by administration of high-dose adriamycin to breast carcinoma patients].
Adachi K; Onodera T; Minami T; Murata N; Mashiko N; Sato T; Yazawa C
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2560-3. PubMed ID: 3619464
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
18. Optimal control of cyclophosphamide-induced emesis.
Stewart A
Oncology; 1996 Jun; 53 Suppl 1():32-8. PubMed ID: 8692548
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.
Shivaprakash G; Udupa KS; Sarayu V; Thomas J; Gupta V; Pallavi LC; Pemminati S
Indian J Pharmacol; 2017; 49(6):451-457. PubMed ID: 29674800
[TBL] [Abstract][Full Text] [Related]
20. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Gez E; Warner-Efraty E; Ben-Yosef R; Ben-Baruch N; Yitzhaki N; Uziely B; Brufman G; Biran S
Oncology; 1987; 44(4):237-9. PubMed ID: 3614813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
